Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ROS1 | P08922 | 1/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.56 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 6/20 | 0.55 |
| ▸ | CA2 | P00918 | 6/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.47 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325239 | 1.00 | MAPT (0.60) | MAPTLMNAROS1CDK5ACVR1 | |
| SCHEMBL20436331 | 1.00 | MAPT (0.60) | MAPTLMNAROS1CDK5ACVR1 | |
| SCHEMBL20436333 | 0.83 | CA1 (0.62) | MAPTLMNAROS1CDK5ACVR1 | |
| SCHEMBL5739473 | 0.83 | CA1 (0.62) | MAPTLMNAROS1CDK5ACVR1 | |
| SCHEMBL30813240 | 0.79 | LRRK2 (0.60) | LRRK2CA1CA2AGTR1CA9 | |
| SCHEMBL6322987 | 0.79 | TGM2 (0.61) | MAPTLRRK2CA1CA2AGTR1 | |
| SCHEMBL7220775 | 0.79 | SMN1; SMN2 (0.40) | MAPTLMNALRRK2CA1CA2 | |
| SCHEMBL6315587 | 0.79 | TGM2 (0.61) | MAPTLRRK2CA1CA2AGTR1 | |
| SCHEMBL16168103 | 0.79 | MAP3K7 (0.46) | MAPTLMNAROS1CDK5ACVR1 | |
| SCHEMBL23612445 | 0.79 | HPGD (0.46) | MAPTLMNALRRK2AGTR1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969729-B2 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2005-11-29 | — | — | US | claimed |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S | 2003-06-19 | — | — | US | claimed |
| JP-2002531498-A | — | — | 2002-09-24 | — | — | JP | claimed |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2002-02-07 | — | — | US | claimed |
| EP-1135123-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| WO-2000033834-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | claimed |
| US-6969729-B2 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2005-11-29 | — | — | US | disclosed |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S | 2003-06-19 | — | — | US | disclosed |
| US-6503898-B1 | Administering 4,7-dibenzyl-5,6-dihydroxy-N,N*-di(m-aminobenzyl)--1,3-diazepin-2-one or salt to treat human immunodeficiency virus infection | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | disclosed |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2002-02-07 | — | — | US | disclosed |
| EP-1135123-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000033834-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | disclosed |
| EP-0432648-B1 | Isatine derivatives, their preparation and use | NEUROSEARCH AS (DK) | 1995-08-02 | — | — | EP | disclosed |
| US-5198461-A | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-03-30 | — | — | US | disclosed |
| EP-0432648-A2 | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | MAPT 1939/4885LMNA 623/4885ROS1 3774/4885 |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | MAPT 1634/4885LMNA 1160/4885ROS1 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.